Leerink Swann Weighs in on Sage Therapeutics, Inc.’s FY2018 Earnings (SAGE)
Sage Therapeutics, Inc. (NASDAQ:SAGE) – Equities researchers at Leerink Swann reduced their FY2018 EPS estimates for Sage Therapeutics in a research report issued on Tuesday. Leerink Swann analyst P. Matteis now forecasts that the biopharmaceutical company will earn ($8.08) per share for the year, down from their previous forecast of ($7.57). Leerink Swann has a “Outperform” rating and a $97.00 price target on the stock. Leerink Swann also issued estimates for Sage Therapeutics’ FY2019 earnings at ($2.55) EPS.
SAGE has been the subject of a number of other research reports. Stifel Nicolaus restated a “buy” rating and issued a $91.00 price objective (down previously from $104.00) on shares of Sage Therapeutics in a research report on Wednesday. J P Morgan Chase & Co reiterated a “buy” rating on shares of Sage Therapeutics in a research report on Thursday, August 31st. Cowen and Company reiterated a “buy” rating and set a $100.00 price target on shares of Sage Therapeutics in a research report on Friday, August 4th. BidaskClub downgraded shares of Sage Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 23rd. Finally, HC Wainwright lifted their price objective on Sage Therapeutics to $86.00 and gave the stock a “neutral” rating in a research report on Friday, August 4th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $86.77.
TRADEMARK VIOLATION NOTICE: “Leerink Swann Weighs in on Sage Therapeutics, Inc.’s FY2018 Earnings (SAGE)” was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/09/15/leerink-swann-weighs-in-on-sage-therapeutics-inc-s-fy2018-earnings-sage.html.
Sage Therapeutics (NASDAQ SAGE) traded down 2.36% during trading on Friday, reaching $63.32. The company had a trading volume of 832,050 shares. The stock’s market capitalization is $2.37 billion. Sage Therapeutics has a 1-year low of $38.30 and a 1-year high of $90.80. The firm has a 50-day moving average of $81.85 and a 200-day moving average of $74.87.
Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by ($0.25). During the same quarter last year, the business earned ($1.08) earnings per share.
Large investors have recently made changes to their positions in the stock. Teachers Advisors LLC grew its position in Sage Therapeutics by 15.0% in the 4th quarter. Teachers Advisors LLC now owns 49,296 shares of the biopharmaceutical company’s stock worth $2,517,000 after purchasing an additional 6,419 shares during the last quarter. Bank of Montreal Can grew its position in Sage Therapeutics by 7,004.1% in the 1st quarter. Bank of Montreal Can now owns 12,006 shares of the biopharmaceutical company’s stock worth $853,000 after purchasing an additional 11,837 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in Sage Therapeutics in the 1st quarter worth about $256,000. Russell Investments Group Ltd. boosted its holdings in shares of Sage Therapeutics by 82.1% in the first quarter. Russell Investments Group Ltd. now owns 19,679 shares of the biopharmaceutical company’s stock valued at $1,399,000 after acquiring an additional 8,872 shares in the last quarter. Finally, Swiss National Bank boosted its holdings in shares of Sage Therapeutics by 3.2% in the first quarter. Swiss National Bank now owns 52,100 shares of the biopharmaceutical company’s stock valued at $3,703,000 after acquiring an additional 1,600 shares in the last quarter.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.